Allergy and Asthma center of North Carolina, PA, High Point Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2007
NCT00500539
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

Allergy and Asthma center of North Carolina, PA, High Point, NC 27262

Active Ingredients

Drugs in Phase 3 Trials (1)

omalizumab (xolair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1